ATRA stock forecast
Our latest prediction for Atara Biotherapeutics, Inc.'s stock price was made on the May 30, 2019 when the stock price was at 22.78$.
In the short term (2weeks), ATRA's stock price should outperform the market by 1.14%. During that period the price should oscillate between -9.09% and +14.55%.
In the medium term (3months), ATRA's stock price should outperform the market by 1.55%. During that period the price should oscillate between -20.35% and +32.42%.Get email alerts
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -6.10$ per share.
The book value per share is 9.98$
Three months stock forecastMay 30, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|